source
- Boehringer Ingelheim partners with Envisagenics on $1 billion AI-driven oncology collaborationBoehringer Ingelheim and AI drug discovery firm Envisagenics have signed a potential $1 billion multi‑year agreement to validate tumor‑specific targets. The deal will see Boehringer use Envisagenic…
- FDA approves Lilly's new combination therapy for advanced breast cancerThe U.S. Food and Drug Administration has granted approval for a new combination drug regimen developed by Eli Lilly for patients with an advanced form of breast cancer. The therapy pairs two agen…